In the remaining 12 patients, a new VVIR unit with Autocapture function was connected to an old ventricular pacing lead.
Pacemakers
The implanted pacemakers with ventricular Autocapture function were the VVIR pacemaker Regency SR 1 2400L (12 patients) or, the DDDR pacemakers Affinity DR (St. Jude Medical-Pacesetter, Sylmar, CA, US) (2 patients) or Integrity DR (1 patient). The Autocapture pacing system measures the ventricular capture thresholds and programs an automatic pulse amplitude to a setting 0.3 V above the measured threshold, and verifies that capture has occurred on a beat-by-beat basis by measuring the ER signal in the ventricle after each pacing pulse. If no ER is detected, a 4.5-V safety backup pulse is emitted 62.5 ms after the initial pulse. To keep the stimulation amplitude as low as possible, a threshold search is conducted every 8 hours or after every loss of two consecutive captures followed by a backup pulse. The differentiation of the ER and polarization signal (PS) is crucial in determining if myocardial depolarization has occurred. The PS is the residual electrical charge from a pacing pulse and it must be small compared to the ER. If the PS is . 60% of the proposed ER sensitivity setting, Autocapture is not recommended.
Pacing Leads
All of the patients had a previously implanted ventricular lead (IS-1 standard compatible). Eight patients had the Accufix II DEC (033-212 model) (Telectronics Pacing Systems, Inc., Engelwood, CO, USA) pacing leads. The Accufix II DEC is a bipolar, steroid-eluting, actively fixated screw-in lead. Three patients had bipolar, steroid eluting, passively fixated Excellence 1 (IMD 49 B model) (Vitatron Medical BV, Dieren, the Netherlands) leads. One patient had a CaptureFix (4068 model) (Medtronic, Inc., Minneapolis, MN, USA) pacing lead. The CaptureFix is a bipolar, steroid-eluting, actively fixated screw-in lead. Two patients had the Medtronic CapSure (one of them model 5024M, the other one model 4024). The CapSure is a bipolar, steroid-eluting, passively fixated ventricular lead. The impedance of leads and ventricular stimulation thresholds were measured intraoperatively, and if the results were satisfactory (lead impedance , 800 V, threshold , 1.5 V), the lead was connected to the new pulse generator.
Follow-Up
Follow-up measurements including lead impedance, pacing threshold, PS, and ER signal were performed at predischarge and at 1, 3, 6, 12, and 18 months postimplantation. If the values of PS and ER were acceptable, Autocapture turned On at 1-month control. The mean follow-up period was 9.42 6 5.01 months (range 1-18 months).
Statistical Analysis
Results are presented as mean 6 SD. Statistical analyses were performed by Friedman twoway ANOVA and Wilcoxon test. P values , 0.05 were considered significant.
Results

Implantation
The mean pacing threshold was 1.0 6 0.35 V (range 0.6-1.5 V). The pacing impedance was 546 6 80 V. The intrinsic R wave could not be obtained in two pacemaker dependent patients in spite of a 30/min backup pacing rate. Excluding these two cases, the mean intrinsic R wave amplitude was 7.9 6 4.9 mV (range 1.58-16.4 mV ( Table  I) .
Follow-Up
The pacing threshold and lead impedance measurements did not change significantly during follow-up (P . 0.05). The mean ER signal amplitude was 8.15 6 3.04 mV and the mean PS was 3.8 6 3.04 (median 2.27 mV) at predischarge visit. The ER and the PS signals remained stable in both groups during follow-up (Table II) . In six cases, the results of ER and PS measurements were acceptable for Autocapture at predischarge measurement and 1-month follow-up. The Autocapture turned On in these six patients at 1-month followup. In remaining nine patients, the results of ER sensitivity test were not suitable for Autocapture and the pacing amplitude programmed traditionally to twice the pacing threshold. The mean ER signal was not statistically different, but slightly greater, in the Autocapture suitable group (9.71 6 3.69 vs 7.10 6 5.0 mV, P . 0.05). The mean PS signal was significantly lower in the Autocapture suitable group (1.23 6 0.61 vs 4.60 6 2.56 mV; P , 0.05). Age, lead impedance, pacing threshold, intrinsic R wave measurement, lead age, fixation mechanism, and ER measurements were not statistically different in the Autocapture suitable and not suitable groups (Table III) .
Discussion
Transvenous cardiac pacing in children has been shown to be safe and reliable. It is the preferred method unless cardiovascular structure and limited vascular access necessitate epicardial pacing. The major goals for pacing in childhood are survival of the electrode and longevity of the implanted pacemaker, since they need many re- placements during their life. The Autocapture system that monitors the capture and automatically adjusts and maintains output has been a spectacular invention for the scientists and industry. Accomplishment of this idea leads the implanted pacemaker to operate at low output settings to decrease the battery depletion and an increase in the pacemaker longevity. [1] [2] [3] [4] When replacing a pulse generator, the compatibility of still implanted leads and newer pulse generators must be taken into account because the longevity of endocardial pacing leads is usually longer than pulse generators. The dangers associated with lead extraction are well documented. 7 Removal of an electrically functional lead is an unnecessary procedure unless there is a hazardous lead condition like infection or migration of the lead. 7 The authors preferred the new pacing systems with Autocapture capability since this function can provide longer pulse generator longevity. In addition to the Autocapture function, these pacemakers have all the features of a sophisticated rate responsive pulse generator.
In six cases the previously implanted old leads were found acceptable for Autocapture function according to the results of ER and PS measurements. In the previous reports with recommended leads, the pacemaker was found suitable for programming Autocapture On in 80-100% of the patients. [1] [2] [3] [4] Provenier et al. 8 reported that activation of the Autocapture function was possible in 11 (55%) of 20 patients implanted with a Medronic 4024 CapSure. The authors could not find any previous reports about the compatibility of Autocapture function with old and nonrecommended endocardial pacing leads in children and young adults.
The model and the age of previously implanted pacing leads, lead-fixation mechanism, intrinsic R wave amplitude, patient characteristics, telemetric control parameters, and ER measurements were not correlate with recommendation of Autocapture. The main reason not to activate Autocapture is increased PS . There was no statistical difference between the two groups regarding measured ER signals. During the followup period, no significant fluctuations were observed in pacing threshold, lead impedance, ER, and PS amplitude. This explained why the ER and PS signal measurements did not change with time regardless of lead model and telemetric control parameters.
Conclusion
The present study revealed that the Autocapture function could also be compatible with previously implanted pacing leads. Inappropriate PS measurement was the main reason not to activate Autocapture. However, no constant could be found that would know whether the Autocapture parameters would be suitable or not. So, the estimation of compatibility of the lead with Autocapture function before replacement is impossible now, because standard pacing system analyzers cannot measure ER and PS signals. Implantation of Autocapture pacemakers in patients with previously implanted nonrecommended leads, would be useful, since almost half of them would have the Autocapture system that increases battery longevity.
